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CR  1例  4.2％ 　0例  　0％
PR  2例  8.3％  30例 11.2％
SD  5例 20.8％  78例 29.1％
PD 16例 66.7％ 124例 46.3％
NE  0例  　0％  36例 13.4％
RR  3例 12.5％  30例 11.2％
DCR  8例 33.3％ 108例 40.3％
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表 ₂　胃癌 Pseudoprogression の報告例





① 85M - 4th Nivolumab 6weeks 10weeks
② 55F - 3rd anti-PD-1＋anti-VEGFR2 8weeks 12weeks
③ 64M - 3rd anti-PD-1＋anti-VEGFR2 - -
④ 54M - 1st anti-PD-1＋anti-VEGFR2 8weeks 12weeks
⑤ 64M - 2nd anti-PD-1 8weeks 12weeks
⑥ 61M - 2nd anti-PD-L1 8weeks 12weeks
自験例 60代M 1 4th Nivolumab 6weeks 16weeks
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